A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).

Find Ozempic Complications Latest News, Videos & Pictures on Ozempic Complications and see latest updates, news, information from NDTV.COM. Explore more on Ozempic Complications.

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally ...

Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India, pricing the starter dose at ₹8,800 per month (₹2,200 per week), positioning it as a competitor to Eli Lilly's Mounjaro (priced ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...